glp 1 market share by company of GLP-1 RAs in 2016 and 2017 GLP-1 Receptor Agonist Market Growth

Metabolism: Clinical and Experimental, 59(8), 11901199

doi: 10.1016/S0008-6363(00)00097-3 118 RobertsLJMorrowJD

It found that these drugs may slightly increase the chance of getting gallstones (cholelithiasis) and acid reflux (GERD)

Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results

Thus, BPC-157 possesses gastrointestinal protective properties, including alleviation from: Ulcers Bowel issues Crohns disease BPC-157 has the potential in medicine to act as an effective systemic healing agent, whether administered by injection or orally